Putative Therapeutic Impact of Inflammasome Inhibitors against COVID-19-Induced ARDS

Curr Med Chem. 2023;30(12):1406-1419. doi: 10.2174/0929867329666220906111550.

Abstract

Given the importance of COVID-19-induced ARDS, recently, researchers have strived to determine underlying mechanisms involved in the inflammatory responses. In this regard, inflammasomes possess a distinct priority for cytokine storm occurrence and, subsequently, ARDS progression in ill patients with SARS-CoV-2 infection. In this minireview, the characteristics of known inflammasome inhibitors and designed research in this field were concretely deciphered.

Keywords: ARDS; COVID-19; NLRP3; SARS-CoV-2; inflammasome; inhibitors.

MeSH terms

  • COVID-19* / complications
  • Humans
  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Respiratory Distress Syndrome* / drug therapy
  • SARS-CoV-2

Substances

  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein